Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 407899

Drug Profile

SAR 407899

Alternative Names: SAR407899; SAR407899A

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Analgesics; Cardiovascular therapies; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Syndrome X
  • Discontinued Diabetic nephropathies; Diabetic neuropathies; Erectile dysfunction; Hypertension; Kidney disorders; Pulmonary hypertension

Most Recent Events

  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Syndrome X (microvascular angina) in 2022
  • 23 Jul 2018 Sanofi terminates a phase II trial in Syndrome X in Sweden, Denmark, South Korea, Netherlands, USA, due to slow recruitment (PO) (NCT03236311)
  • 19 Sep 2017 Phase-II clinical trials in Syndrome X in Denmark (PO) (NCT03236311)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top